Current approaches in the treatment of relapsed and refractory acute myeloid leukemia

Journal of Clinical Medicine

Volumn 4, Issue 4, 2015, Pages 665-695

  Ramos, Nestor R ^a   Mo, Clifton C ^b   Karp, Judith E ^c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AML; Eoplasm metastasis; Leukemia; Relapse; Salvage therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACLARUBICIN; BORTEZOMIB; CLADRIBINE; CLOFARABINE; CYTARABINE; CYTARABINE PLUS DAUNORUBICIN; DAUNORUBICIN; ELACYTARABINE; ETOPOSIDE; EVEROLIMUS; FLAVOPIRIDOL; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GLASDEGIB; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; IDARUBICIN; LENALIDOMIDE; LINTUZUMAB; MITOXANTRONE; PRAVASTATIN; RAPAMYCIN; RUXOLITINIB; SONIDEGIB; TOSEDOSTAT; UNINDEXED DRUG; VENETOCLAX; VORINOSTAT; VOSAROXIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CELL THERAPY; CYTOTOXICITY; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; HUMAN; LOW INTENSITY THERAPY; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY PERIOD; REVIEW; SALVAGE THERAPY; TREATMENT RESPONSE; VACCINATION;

EID: 84964480010     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. American Cancer Society Cancer Facts & Figures 2015; American Cancer Society: Atlanta GA USA 2015; p 4
2. Walter RB; Othus M; Burnett AK; Lowenberg B; Kantarjian HM; Ossenkoppele G J; Hills R K; Ravandi F; Pabst T; Evans A; et al Resistance prediction in aml: Analysis of 4601 patients from MRC/NCRI HOVON/SAKK SWOC and MD Anderson Cancer Center Leukemia 2014 29 312–320
3. Lowenberg B; Downing JR; Burnett A Acute myeloid leukemia N Engl J Med 1999 341 1051–1062
4. Bergua JM; Montesinos P; Martinez-Cuadrón D; Fernández-Abellán P; Serrano J; Sayas MJ; Prieto-Fernandez J; Garcia R; Garcia-Huerta AJ; Barrios M; et al A rognostic index for patients with refractory or in first relapsed acute myeloid leukemia treated with FLAG-ida or FLAGO-ida Blood 2014 124 1049
5. Breems DA; Van Putten WL; Huijgens PC; Ossenkoppele GJ; Verhoef GE; erdonck LF; Vellenga E; De Greef GE; Jacky E; Van der Lelie J; et al Prognostic index for adult patients with acute myeloid leukemia in first relapse J Clin Oncol 2005 23 1969–1978
6. Kurosawa S; Yamaguchi T; Miyawaki S; Uchida N; Sakura T; Kanamori H; Usuki K; Yamashita T; Okoshi Y; Shibayama H; et al Prognostic factors and outcomes of adult atients with acute myeloid leukemia after first relapse Haematologica 2010 95 1857–1864
7. Pemmaraju N Kantarjian H Garcia-Manero G Pierce S Cardenas-Turanzas M Cortes J Ravandi F Improving outcomes for patients with acute myeloid leukemia in first relapse A single center experience Am J Hematol 2015 90 27 30
8. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N Engl J Med 2013 368 2059–2074
9. Ding L; Ley TJ; Larson DE; Miller CA; Koboldt DC; Welch JS; Ritchey JK; Young MA; Lamprecht T; McLellan MD; et al Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing Nature 2012 481 506–510
10. Meggendorfer M; Alpermann T; Perglerová K; Kern W; Schnittger S; Haferlach C; Haferlach T Genetic patterns of relapsed aml differ significantly from first manifestation and are dependent on cytogenetic risk groups at diagnosis: Results in 175 patients with paired samples Blood 2014 124 1029
11. Hourigan CS; Karp JE New considerations in the design of clinical trials for the treatment of acute leukemia Clin Investig 2011 1 509–517
12. Karanes C; Kopecky KJ; Head DR; Grever MR; Hynes HE; Kraut EH; Vial RH; Lichtin A; Nand S; Samlowski WE; et al A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study Leuk Res 1999 23 787–794
13. Herzig RH; Lazarus HM; Wolff SN; Phillips GL; Herzig GP High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia J Clin Oncol 1985 3 992–997
14. Lee SR; Yang DH; Ahn JS; Kim YK; Lee JJ; Choi YJ; Shin HJ; Chung JS; Cho YY; Chae YS; et al The clinical outcome of flag chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia J Korean Med Sci 2009 24 498–503
15. Montillo M; Mirto S; Petti MC; Latagliata R; Magrin S; Pinto A; Zagonel V; Mele G; Tedeschi A; Ferrara F Fludarabine cytarabine and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia Am J Hematol 1998 58 105–109
16. Virchis A; Koh M; Rankin P; Mehta A; Potter M; Hoffbrand AV; Prentice HG Fludarabine cytosine arabinoside granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes Br J Haematol 2004 124 26–32
17. Milligan DW; Wheatley K; Littlewood T; Craig JI; Burnett AK Fludarabine and cytosine are less effective than standard ade chemotherapy in high-risk acute myeloid leukemia and addition of G-CSF and ATRA are not beneficial: Results of the MRC AML-HR randomized trial Blood 2006 107 4614–4622
18. Martin MG; Welch JS; Augustin K; Hladnik L; DiPersio JF; Abboud CN ladribine in the treatment of acute myeloid leukemia: A single-institution experience Clin Lymphoma Myeloma 2009 9 298–301
19. Wrzesien-Kus A; Robak T; Lech-Maranda E; Wierzbowska A; Dmoszynska A; Kowal M; Holowiecki J; Kyrcz-Krzemien S; Grosicki S; Maj S; et al A multicenter open non-comparative phase II study of the combination of cladribine (2-chlorodeoxyadenosine) cytarabine and G-CSF as induction therapy in refractory acute myeloid leukemia—A report of the polish adult leukemia group (PALG) Eur J Haematol 2003 71 155–162
20. Price SL; Lancet JE; George TJ; Wetzstein GA; List AF; Ho VQ; Fernandez HF; Pinilla-Ibarz J; Kharfan-Dabaja MA; Komrokji RS Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens Leuk Res 2011 35 301–304
21. Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Holowiecki J; Kyrcz-Krzemien S; Grosicki S; Giebel S; Skotnicki AB; et al Cladribine combined with high doses of arabinoside cytosine mitoxantrone and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: A final report of the polish adult leukemia group Eur J Haematol 2008 80 115–126
22. Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F Mitoxantrone etoposide and intermediate-dose cytarabine: An effective and tolerable regimen for the treatment of refractory acute myeloid leukemia J Clin Oncol 1991 9 1210–1214
23. Trifilio SM; Rademaker AW; Newman D; Coyle K; Carlson-Leuer K; Mehta J; ltman J; Frankfurt O; Tallman MS Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia Leuk Res 2012 36 394–396
24. Greenberg PL; Lee SJ; Advani R; Tallman MS; Sikic BI; Letendre L; Dugan K; Lum B; Chin DL; Dewald G; et al Mitoxantrone etoposide and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995) J Clin Oncol 2004 22 1078–1086
25. Kohrt HE; Patel S; Ho M; Owen T; Pollyea DA; Majeti R; Gotlib J; Coutre S; Liedtke M; Berube C; et al Second-line mitoxantrone etoposide and cytarabine for acute myeloid leukemia: A single-center experience Am J Hematol 2010 85 877–881
26. Halpern AB; Estey EH; Othus M; Orlowski KF; Powell MA; Chen TL; Becker PS; Scott BL; Hendrie PC; Ostronoff F; et al Mitoxantrone etoposide and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS): A phase 1 study Blood 2014 124 3730
27. Archimbaud E; Thomas X; Leblond V; Michallet M; Fenaux P; Cordonnier C; Dreyfus F; Troussard X; Jaubert J; Travade P; et al Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: Long-term follow-up of the etoposide mitoxantrone and cytarabine-86 trial J Clin Oncol 1995 13 11–18
28. Link H Freund M Diedrich H Wilke H Austein J Henke M Wandt H Fackler-Schwalbe E Schlimok G Hoffmann R et al Mitoxantrone cytosine arabinoside and vp-16 in 36 patients with relapsed and refractory acute myeloid leukemia Haematol Blood Transfus 1990 33 322 325
29. De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; iglino M; Di Grazia C; Ballerini F; et al Liposomal daunorubicin fludarabine and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia Ann Hematol 2014 93 2011–2018
30. Litzow MR; Wang XV; Carroll MP; Karp JE; Ketterling R; Kaufmann SH; Lazarus HM; Luger SM; Paietta EM; Rowe JM; et al A randomized phase II trial of three novel regimens for relapsed/ refractory acute myeloid leukemia (AML) demonstrates encouraging results with a flavopiridol-based regimen: Results of eastern cooperative oncology group (ECOG) trial E1906 Blood 2014 124 3742
31. Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD Sequential flavopiridol cytosine arabinoside and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia Clin Cancer Res 2007 13 4467–4473
32. Karp JE; Smith BD; Resar LS; Greer JM; Blackford A; Zhao M; Moton-Nelson D; Alino K; Levis MJ; Gore SD; et al Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias Blood 2011 117 3302–3310
33. Faderl S; Gandhi V; O'Brien S; Bonate P; Cortes J; Estey E; Beran M; Wierda W; Garcia-Manero G; Ferrajoli A; et al Results of a phase 1-2 study of clofarabine in ombination with cytarabine (ARA-C) in relapsed and refractory acute leukemias Blood 2005 105 940–947
34. Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; et al Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients Am J Hematol 2012 87 1047–1051
35. Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; et al Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the classic I trial J Clin Oncol 2012 30 2492–2499
36. Becker PS; Kantarjian HM; Appelbaum FR; Petersdorf SH; Storer B; Pierce S; Shan J; Hendrie PC; Pagel JM; Shustov AR; et al Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia Br J Haematol 2011 155 182–189
37. Becker PS; Kantarjian HM; Appelbaum FR; Storer B; Pierce S; Shan J; Faderl S; Estey EH Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia Haematologica 2013 98 114–118
38. Yu W; Mao L; Qian J; Qian W; Meng H; Mai W; Tong H; Tong Y; Jin J Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: A single-center experience Ann Hematol 2013 92 1091–1100
39. Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; et al First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia J Clin Oncol 2011 29 979–985
40. Cortes JE; Goldberg SL; Feldman EJ; Rizzeri DA; Hogge DE; Larson M; Pigneux A; Recher C; Schiller G; Warzocha K; et al Phase II multicenter randomized trial of CPX-351 (cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML Cancer 2015 121 234–242
41. Pemmaraju N; Kantarjian H; Kadia T; Cortes J; Borthakur G; Newberry K; Garcia- anero G; Ravandi F; Jabbour E; Dellasala S; et al A phase I/II study of the janus kinase (JAK) 1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia Clin Lymphoma Myeloma Leuk 2015 15 171–176
42. Eghtedar A; Verstovsek S; Estrov Z; Burger J; Cortes J; Bivins C; Faderl S; Ferrajoli A; Borthakur G; George S; et al Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias including postmyeloproliferative neoplasm acute myeloid leukemia Blood 2012 119 4614–4618
43. Recher C; Beyne-Rauzy O; Demur C; Chicanne G; Dos Santos C; Mas VM; Benzaquen D; Laurent G; Huguet F; Payrastre B Antileukemic activity of rapamycin in acute myeloid leukemia Blood 2005 105 2527–2534
44. Liesveld JL; O'Dwyer K; Walker A; Becker MW; Ifthikharuddin JJ; Mulford D; Chen R; Bechelli J; Rosell K; Minhajuddin M; et al A phase I study of decitabine and rapamycin in relapsed/refractory AML Leuk Res 2013 37 1622–1627
45. Park S; Chapuis N; Saint Marcoux F; Recher C; Prebet T; Chevallier P; Cahn JY; Leguay T; Bories P; Witz F; et al A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for aml patients in first relapse Leukemia 2013 27 1479–1486
46. Lowenberg B; Morgan G; Ossenkoppele GJ; Burnett AK; Zachee P; Duhrsen U; Dierickx D; Muller-Tidow C; Sonneveld P; Krug U; et al Phase I/II clinical study of tosedostat an inhibitor of aminopeptidases in patients with acute myeloid leukemia and myelodysplasia J Clin Oncol 2010 28 4333–4338
47. Cortes J; Feldman E; Yee K; Rizzieri D; Advani AS; Charman A; Spruyt R; Toal M; Kantarjian H Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): A randomised open-label phase 2 study Lancet Oncol 2013 14 354–362
48. Schaefer EW; Loaiza-Bonilla A; Juckett M; DiPers JF; Roy V; Slack J; Wu WT; Laumann K; Espinoza-Delgado I; Gore SD; et al A phase 2 study of vorinostat in acute myeloid leukemia Haematol Hematol J 2009 94 1375–1382
49. Walter RB; Medeiros BC; Gardner KM; Orlowski KF; Gallegos L; Scott BL; Hendrie PC; Estey EH Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: A phase I/II study Haematologica 2014 99 54–59
50. Gojo I; Tan M; Fang HB; Sadowska M; Lapidus R; Baer MR; Carrier F; Beumer JH; Anyang BN; Srivastava RK; et al Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed refractory or high-risk acute myeloid leukemia Clin Cancer Res 2013 19 1838–1851
51. Stein E; Tallman M; Pollyea DA; Flinn IW; Fathi AT; Stone RM; Levine RL; Agresta S; Schenkein D; Yang H; et al Clinical safety and activity in a phase I trial of AG-221 a first in class potent inhibitor of the IDH2-mutant protein in patients with IDH2 mutant positive advanced hematologic malignancies In Proceedings of the 105th Annual Meeting of the American Association for Cancer Research San Diego CA USA 6–8 April 2014
52. Roboz GJ; Rosenblat T; Arellano M; Gobbi M; Altman JK; Montesinos P; O’Connell C; Solomon SR; Pigneux A; Vey N; et al International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia J Clin Oncol 2014 32 1919–1926
53. Lancet JE; Ravandi F; Ricklis RM; Cripe LD; Kantarjian HM; Giles FJ; List AF; Chen T; Allen RS; Fox JA; et al A phase Ib study of vosaroxin an anticancer quinolone derivative in patients with relapsed or refractory acute leukemia Leukemia 2011 25 1808–1814
54. Ravandi F; Ritchie E; Sayar H; Lancet J; Craig MD; Vey N; Strickland SA; Schiller G; Jabbour E; Erba HP; et al Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: Results of a phase 3 double-blind randomized controlled multinational study (VALOR) Blood 2014 124 LBA-6
55. Kornblau SM; Banker DE; Stirewalt D; Shen D; Lemker E; Verstovsek S; Estrov Z; Faderl S; Cortes J; Beran M; et al Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose ARA-C: A phase 1 study Blood 2007 109 2999–3006
56. Advani AS; McDonough S; Copelan E; Willman C; Mulford DA; List AF; Sekeres MA; Othus M; Appelbaum FR SWOG0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia Br J Haematol 2014 167 233–237
57. Advani AS; Elson P; Kalaycio ME; Mukherjee S; Gerds AT; Hamilton BK; Hobson S; Smith A; Rush ML; Bogati S; et al Bortezomib + MEC (mitoxantrone etoposide cytarabine) for relapsed/refractory acute myeloid leukemia: Final results of an expanded phase 1 trial Blood 2014 124 978
58. Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities Clin Lymphoma Myeloma Leuk 2012 12 341–344
59. Pardee TS; Stadelman K; Isom S; Ellis LR; Berenzon D; Hurd DD; Harrelson R; Manuel M; Dralle S; Lyerly S; et al The mitochondrial metabolism inhibitor CPI-613 is highly active in combination with high dose ARA-C (HIDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML) Blood 2014 124 3744
60. Konopleva M; Pollyea DA; Potluri J; Chyla BJ; Busman T; McKeegan E; Salem A; Zhu M; Ricker JL; Blum W; et al A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML) Blood 2014 124 118
61. Thol F; Schlenk RF Gemtuzumab ozogamicin in acute myeloid leukemia revisited Expert Opin Biol Ther 2014 14 1185–1195
62. Petersdorf S; Kopecky K; Stuart RK; Larson RA; Nevill TJ; Stenke L; Slovak ML; Tallman MS; Willman CL; Erba H; et al Preliminary results of Southwest Oncology Group Sstudy S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia Blood 2009 114 326–327
63. Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terre C; et al Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse Am J Hematol 2014 89 399–403
64. Sutherland MSK; Walter RB; Jeffrey SC; Burke PJ; Yu CP; Kostner H; Stone I; Ryan MC; Sussman D; Lyon RP; et al SGN-CD33A: A novel CD33-targeting antibody- rug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML Blood 2013 122 1455–1463
65. Stein EM; Stein A; Walter RB; Fathi AT; Lancet JE; Kovacsovics TJ; Advani AS; DeAngelo DJ; O'Meara MM; Zhao B; et al Interim analysis of a phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML) Blood 2014 124 623
66. Feldman EJ; Brandwein J; Stone R; Kalaycio M; Moore J; O’Connor J; Wedel N; Roboz GJ; Miller C; Chopra R; et al Phase III randomized multicenter study of a umanized anti-CD33 monoclonal antibody lintuzumab in combination with chemotherapy versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia J Clin Oncol 2005 23 4110–4116
67. Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; et al Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAB engineered for optimal ADCC Leukemia 2014 28 2213–2221
68. Smith BD; Roboz GJ; Walter RB; Altman JK; Ferguson A; Curcio TJ; Orlow ki KF; Garrett L; Busfield SJ; Barnden M; et al First-in man phase 1 study of CSL362 (anti-IL3Rα/anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse Blood 2014 124 120
69. Laszlo GS; Gudgeon CJ; Harrington KH; Dell’Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody AMG 330 against human AML Blood 2014 123 554–561
70. Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; et al Preclinical characterization of AMG 330 a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia Mol Cancer Ther 2014 13 1549–1557
71. Uy G; Stewart S; Baughman J; Rettig M; Chichili G; Bonvini E; Wigginton J; Lechleider R; DiPersio J A phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML) J Immun Ther Cancer 2014 2 87
72. Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B;et al Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 × 33 bispecific killer cell engager and ADAM17 inhibition Clin Cancer Res 2013 19 3844–3855
73. Wang QS; Wang Y; Lv HY; Han QW; Fan H; Guo B; Wang LL; Han WD Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia Mol Ther 2015 23 184–191
74. Gill S Tasias SK Ruella M Shestova O Li Y Porter D L Carroll M Danet-Desnoyers G Scholler J Grupp S A et al Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells Blood 2014 123 2343–2354
75. Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo Leukemia 2014 28 1596–1605
76. Berneman ZN; Van de Velde AL; Willemen Y; Anguille S; Saevels K; Germonpré P; Huizing MT; Peeters M; Snoeckx A; Parizel P; et al Vaccination with WT1 mRNA-electroporated dendritic cells: Report of clinical outcome in 66 cancer patients Blood 2014 124 310
77. Rosenblat TL; Frattini MG; Chanel SM; Dao T; Bernal Y; Jurcic JG; Zhang R; Simancek P; Tallman MS; Scheinberg DA; et al Phase II trial of WT1 analog peptide vaccine in patients with acute myeloid leukemia (AML) in complete remission (CR) Blood 2012 120 3624
78. Goswami M; Hensel N; Smith BD; Prince GT; Qin L; Levitsky HI; Strickland SA; Jagasia M; Savani BN; Fraser JW; et al Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues Leukemia 2014 28 1167–1170
79. Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; et al Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study J Clin Oncol 2009 27 5195–5201
80. Chapuis AG; Ragnarsson GB; Nguyen HN; Chaney CN; Pufnock JS; Schmitt TM; Duerkopp N; Roberts IM; Pogosov GL; Ho WY; et al Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients Sci Transl Med 2013 5 doi:101126/scitranslmed3004916
81. Miller JS; Soignier Y; Panoskaltsis-Mortari A; McNearney SA; Yun GH; Fautsch SK; McKenna D; Le C; Defor TE; Burns LJ; et al Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 2005 105 3051–3057
82. Armistead PM; de Lima M; Pierce S; Qiao W; Wang X; Thall PF; Giralt S; Ravandi F; Kantarjian H; Champlin R; et al Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia Biol Blood Marrow Transplant 2009 15 1431–1438
83. Shimoni A; Hardan I; Shem-Tov N; Yerushalmi R; Nagler A Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: Long-term follow-up Leukemia 2010 24 1050–1052
84. Sebert M; Porcher R; Robin M; Ades L; Boissel N; Raffoux E; Xhaard A; Dhedin N; Larghero J; Himberlin C; et al Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML Bone Marrow Transplant 2015 50 74–81
85. Bejanyan N; Oran B; Shanley R; Warlick E; Ustun C; Vercellotti G; Verneris M; Wagner JE; Weisdorf D; Brunstein C Clinical outcomes of aml patients relapsing after matched-related donor and umbilical cord blood transplantation Bone Marrow Transplant 2014 49 1029–1035
86. Itonaga H; Tsushima H; Taguchi J; Fukushima T; Taniguchi H; Sato S; Ando K; Sawayama Y; Matsuo E; Yamasaki R; et al Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki Transplant Group experience Blood 2013 121 219–225
87. Takami A; Yano S; Yokoyama H; Kuwatsuka Y; Yamaguchi T; Kanda Y; Morishima Y; Fukuda T; Miyazaki Y; Nakamae H; et al Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A retrospective analysis by the adult acute myeloid leukemia working group of the Japan Society for Hematopoietic Cell Transplantation Biol Blood Marrow Transplant 2014 20 1785–1790
88. Schroeder T; Czibere A; Platzbecker U; Bug G; Uharek L; Luft T; Giagounidis A; Zohren F; Bruns I; Wolschke C; et al Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation Leukemia 2013 27 1229–1235
89. Ghobadi A; Fiala MA; Abboud CN; Cashen AF; Eissenberg L; Graubert T; Jacoby MA; Pusic I; Schroeder MA; Stockerl-Goldstein KE; et al A phase I study of azacitidine after donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation Blood 2013 122 3320
90. O’Donnell MR; Tallman MS; Abboud CN; Altman JK; Appelbaum FR; Arber DA; Attar E; Borate U; Coutre SE; Damon LE; et al Acute myeloid leukemia version 22013 J Nat Compr Cancer Netw 2013 11 1047–1055
91. Gandhi V; Estey E; Keating MJ; Plunkett W Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy J Clin Oncol 1993 11 116–124
92. Chow KU; Boehrer S; Napieralski S; Nowak D; Knau A; Hoelzer D; Mitrou PS; Weidmann E In AML cell lines ARA-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation apoptosis and disruption of mitochondrial membrane potential Leuk Lymphoma 2003 44 165–173
93. Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; et al Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 trial) Leukemia 1999 13 1214–1220
94. Cooper T; Ayres M; Nowak B; Gandhi V Biochemical modulation of cytarabine triphosphate by clofarabine Cancer Chemother Pharmacol 2005 55 361–368
95. Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; et al G-CSF priming clofarabine and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm Am J Hematol 2014 doi:101002/ajh23927
96. Verdonck LF; Lokhorst HM; Roovers DJ; van Heugten HG Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: Implications for liposome-encapsulated daunorubicin Leuk Res 1998 22 249–256
97. Ermacora A; Michieli M; Pea F; Visani G; Bucalossi A; Russo D Liposome encapsulated daunorubicin (daunoxome) for acute leukemia Haematologica 2000 85 324–325
98. Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T;Hawtin R; Craig AR; Ravandi F; et al A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia Haematologica 2014 100 231–237
99. Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrozek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; et al IDH1 and IDH2 gene utations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study J Clin Oncol 2010 28 2348–2355
100. Stuart SD; Schauble A; Gupta S; Kennedy AD; Keppler BR; Bingham PM; Zachar Z A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process Cancer Metab 2014 2 doi:101186/2049-3002-2-4
101. Ben-Batalla I; Schultze A; Wroblewski M; Erdmann R; Heuser M; Waizenegger JS; Riecken K; Binder M; Schewe D; Sawall S; et al Axl a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma Blood 2013 122 2443–2452
102. Uy GL; Rettig MP; Motabi IH; McFarland K; Trinkaus KM; Hladnik LM; Kulkarni S; Abboud CN; Cashen AF; Stockerl-Goldstein KE; et al A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia Blood 2012 119 3917–3924
103. Konig H; Levis M Targeting FLT3 to treat leukemia Expert Opin Ther Targets 2015 19 37–54
104. Pratz KW; Sato T; Murphy KM; Stine A; Rajkhowa T; Levis M FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML Blood 2010 115 1425–1432
105. Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J et al Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status J Clin Oncol 2013 31 3681–3687
106. Wander SA; Levis MJ; Fathi AT The evolving role of FLT3 inhibitors in acute myeloid leukemia: Quizartinib and beyond Ther Adv Hematol 2014 5 65–77
107. Cortes JE; Tallman MS; Schiller G; Trone D; Gammon G; Goldberg S; Perl AE; Marie JP; Martinelli G; Levis M Results of a phase 2 randomized open-label study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML) Blood 2013 122 494
108. Levis MJ; Perl AE; Dombret H; Dohner H; Steffen B; Rousselot P; Martinelli G; Estey EH; Burnett AK; Gammon G; et al Final results of a phase 2 open-label monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation Blood 2012 120 673
109. Röllig C; Müller-Tidow C; Hüttmann A; Noppeney R; Kunzmann V; Baldus CD; Brandts CH; Krämer A; Schäfer-Eckart K; Neubauer A; et al Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: Results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial 2014 124 6
110. Hourigan CS; McCarthy P; de Lima M Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation Biol Blood Marrow Transplant 2014 20 154–163
111. Chen YB; Li S; Lane AA; Connolly C; Del Rio C; Valles B; Curtis M; Ballen K; Cutler C; Dey BR; et al Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for FMS-like tyrosine kinase 3 internal tandem duplication acute yeloid leukemia Biol Blood Marrow Transplant 2014 20 2042–2048
112. Sammons SL; Pratz KW; Smith BD; Karp JE; Emadi A Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant Am J Hematol 2014 89 936–938
113. Grunwald MR; Levis MJ FLT3 inhibitors for acute myeloid leukemia: A review of their efficacy and mechanisms of resistance Int J Hematol 2013 97 683–694
114. Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; et al Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia Blood 2013 122 3607–3615
115. Lee HK; Kim HW; Lee IY; Lee J; Lee J; Jung DS; Lee SY; Park SH; Hwang H; Choi JS; et al G-749 a novel FLT3 kinase inhibitor can overcome drug resistance for the treatment of acute myeloid leukemia Blood 2014 123 2209–2219
116. Keegan K; Li C; Li ZH; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang LM; Weidner M; et al Preclinical evaluation of AMG 925 a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia Mol Cancer Ther 2014 13 880–889
117. Xiang Z; Zhao Y; Mitaksov V; Fremont DH; Kasai Y; Molitoris A; Ries RE; Miner TL; McLellan MD; DiPersio JF; et al Identification of somatic JAK1 mutations in patients with acute myeloid leukemia Blood 2008 111 4809–4812
118. Shadman M; Mawad R; Dean C; Shannon-Dorcy K; Sandhu V; Hendrie PC; Scott BL; Walter RB; Becker PS; Pagel J; et al Idarubicin cytarabine and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome Blood 2014 124 3732
119. Kobune M; Takimoto R; Murase K; Iyama S; Sato T; Kikuchi S; Kawano Y; Miyanishi K; Sato Y; Niitsu Y; et al Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells Cancer Sci 2009 100 948–955
120. Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; et al CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330 Blood 2014 123 356
121. Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang W-C; Bretzlaff W; et al T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia Blood 2013 122 3138–3148
122. Hourigan CS; Levitsky HI Evaluation of current cancer immunotherapy: Hemato-oncology Cancer J (Sudbury Mass) 2011 17 309–324
123. Jabbour E; Daver N; Champlin R; Mathisen M; Oran B; Ciurea S; Khouri I; Cornelison AM; Ghanem H; Cardenas-Turanzas M;et al Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy Am J Hematol 2014 89 395–398
124. Walter RB; Buckley SA; Pagel JM; Wood BL; Storer BE; Sandmaier BM; Fang M; Gyurkocza B; Delaney C; Radich JP; et al Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission Blood 2013 122 1813–1821
125. Duval M; Klein JP; He W; Cahn JY; Cairo M; Camitta BM; Kamble R; Copelan E; de Lima M; Gupta V; et al Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure J Clin Oncol 2010 28 3730–3738
126. Luznik L; O’Donnell PV; Symons HJ; Chen AR; Leffell MS; Zahurak M; Gooley TA; Piantadosi S; Kaup M; Ambinder RF; et al HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose posttransplantation cyclophosphamide Biol Blood Marrow Transplant 2008 14 641–650
127. Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; et al Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts Biol Blood Marrow Transplant 2014 20 1573–1579
128. Craddock C; Labopin M; Houhou M; Robin M; Finke J; Chevallier P; Yakoub-Agha I; Bourhis J-H; Sengelov H; Blaise D; et al Activity and tolerability of azacitidine in patients who relapse after allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) and myelodysplasia (MDS): A survey from the european society for blood and marrow transplantation (EBMT) Blood 2014 124 2506–2506
129. Sarkozy C; Gardin C; Gachard N; Merabet F; Turlure P; Malfuson JV; Pautas C; Micol JB; Thomas X; Quesnel B; et al Outcome of older patients with acute myeloid leukemia in first relapse Am J Hematol 2013 88 758–764
130. Tawfik B; Sliesoraitis S; Lyerly S; Klepin HD; Lawrence J; Isom S; Ellis LR; Manuel M; Dralle S; Berenzon D; et al Efficacy of the hypomethylating agents as frontline salvage or consolidation therapy in adults with acute myeloid leukemia (AML) Ann Hematol 2014 93 47–55
131. Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP 5-azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy Am J Hematol 2013 88 601–605
132. Ritchie EK; Feldman EJ; Christos PJ; Rohan SD; Lagassa CB; Ippoliti C; Scandura JM; Carlson K; Roboz GJ Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia Leuk Lymphoma 2013 54 2003–2007
133. Bejar R; Lord A; Stevenson K; Bar-Natan M; Perez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; et al TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients Blood 2014 124 2705–2712
134. Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; et al Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias Leukemia 2011 25 1147–1152
135. Estey EH Primacy of resistance rather than toxicity in determining outcome of therapy for AML Clin Lymphoma Myeloma Leuk 2014 14 S56–S58
136. Hourigan CS; Karp JE Minimal residual disease in acute myeloid leukaemia Nat Rev Clin Oncol 2013 10 460–471
137. Meyers J; Yu Y; Kaye JA; Davis KL Medicare fee-for-service enrollees with primary acute myeloid leukemia: An analysis of treatment patterns survival and healthcare resource utilization and costs Appl Health Econ Health Policy 2013 11 275–286
138. Hourigan CS; Karp JE Development of therapeutic agents for older patients with acute myelogenous leukemia Curr Opin Investig Drugs 2010 11 669–677
139. Pemovska T; Kontro M; Yadav B; Edgren H; Eldfors S; Szwajda A; Almusa H; Bespalov MM; Ellonen P; Elonen E; et al Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia Cancer Discov 2013 3 1416–1429
140. Becker PS; Oehler V; Estey EH; Martins T; Perdue A; David J; Chien S; Hendrie PC; Ostronoff F; Blau CA Feasibility trial of individualized therapy for relapsed or refractory acute myeloid leukemia based on a high throughput in vitro drug sensitivity assay Blood 2014 124 3748
141. Hourigan CS; Karp JE Personalized therapy for acute myeloid leukemia Cancer Discov 2013 3 1336–1338
142. Konoplev S; Rassidakis GZ; Estey E; Kantarjian H; Liakou CI; Huang X; Xiao L; Andreeff M; Konopleva M; Medeiros LJ Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype Cancer 2007 109 1152–1156
143. Freeman SD; Virgo P; Couzens S; Grimwade D; Russell N; Hills RK; Burnett AK Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia J Clin Oncol 2013 31 4123–4131
144. Inaba H; Coustan-Smith E; Cao X; Pounds SB; Shurtleff SA; Wang KY; Raimondi SC; Onciu M; Jacobsen J; Ribeiro RC; et al Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia J Clin Oncol 2012 30 3625–3632
145. Grimwade D; Freeman SD Defining minimal residual disease in acute myeloid leukemia: Which platforms are ready for “prime time"? Blood 2014 124 3345–3355
146. Ivey A; Hills RK; Simpson MA; Jovanovic JV; Gilkes AF; Patel Y; Bhudia N; Farah H; Mason J; Wall K; et al Molecular detection of minimal residual disease provides the most powerful independent prognostic factor irrespective of clonal architecture in nucleophosmin (NPML) mutant acute myeloid leukemia 2014 124 70
147. Steinbach D; Bader P; Willasch A; Bartholomae S; Debatin KM; Zimmermann M; Creutzig U; Reinhardt D; Gruhn B Prospective validation of a new method of monitoring minimal residual disease in childhood acute myeloid leukemia Clin Cancer Res 2015 15 1353–1359
148. Goswami M; McGowan KS; Lu K; Jain N; Candia J; Hensel NF; Tang J; Calvo KR; Battiwalla M; Barrett AJ; et al A multigene array for measurable residual disease detection in AML patients undergoing SCT Bone Marrow Transplant 2015 doi:101038/bmt2014326
149. Platzbecker U; Wermke M; Radke J; Oelschlaegel U; Seltmann F; Kiani A; Klut IM; Knoth H; Rollig C; Schetelig J; et al Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the relaza trial Leukemia 2012 26 381–389